NCI begins rewrite of cancer center grant guidelines; will allow clinical investigator support. Goal is to implement P30-P50 working group recommendations, simplify guidelines, Karen Antman tells advisory board.
NCI considers allowing some centers to opt out of site visits.
Board of Scientific Advisors discussion: Are peer reviewers correctly interpreting the guidelines?
Also in this 8-page issue: John Mendelsohn selected for BMS award. National Coalition for Cancer Survivorship and The Wellness Community begin advocacy initiative.
Business & Regulatory Report March edition (8 pages) included.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - The Galleri MCD vote: What FDA asked its advisors to ignore
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
